IMMUNOBIOCHEMICAL BIOMARKERS OF INFLAMMATORY ACTIVITY IN CHILDREN WITH CHRONIC RHEUMATIC HEART DISEASE: CLINICAL AND DIAGNOSTIC SIGNIFICANCE

Authors

Keywords:

chronic rheumatic heart disease, children, rheumatic carditis, TNF-α, IL-10, C-reactive protein, procalcitonin, inflammatory biomarkers, echocardiography, ROC analysis.

Abstract

Chronic rheumatic heart disease (CRHD) in children represents a long-term consequence of immune-mediated cardiac injury following group A β-hemolytic streptococcal infection and may result in persistent valvular damage, recurrent inflammatory activity, progressive cardiac dysfunction, and disability. Conventional clinical and laboratory parameters do not always accurately reflect ongoing biological activity, particularly in patients with limited clinical manifestations or apparent remission.

Objective. The aim of this study was to evaluate serum interleukin-10 (IL-10), tumor necrosis factor-alpha (TNF-α), C-reactive protein (CRP), and procalcitonin (PCT) in children with CRHD, determine their relationships with clinical and echocardiographic manifestations, and assess their diagnostic performance in distinguishing active disease from remission.

Materials and Methods. A clinical observational study was conducted between 2022 and 2025 in Bukhara, Uzbekistan. Sixty children aged 10–17 years were divided into three age- and sex-comparable groups: active CRHD (n=20), CRHD in remission (n=20), and healthy controls (n=20). Serum IL-10 and TNF-α were measured by enzyme-linked immunosorbent assay, CRP by immunoturbidimetry, and PCT by immunoluminescence. Clinical examination, routine laboratory testing, electrocardiography, and echocardiography were performed. Statistical analysis included group comparisons, correlation testing, and receiver operating characteristic analysis.

Results. Mean IL-10 concentrations were 12.4±3.1 pg/mL in active CRHD, 5.6±1.2 pg/mL in remission, and 2.1±0.8 pg/mL in controls (p<0.001). Corresponding TNF-α concentrations were 25.6±5.3, 9.8±2.4, and 3.2±1.1 pg/mL (p<0.001), while CRP levels were 28.5±6.7, 8.4±2.0, and 1.8±0.9 mg/L, respectively (p<0.001). TNF-α correlated positively with disease activity (r=0.72, p<0.01) and mitral regurgitation severity (r=0.67, p<0.01) and inversely with left ventricular ejection fraction (r=−0.61, p<0.01). CRP correlated strongly with body temperature and erythrocyte sedimentation rate. PCT remained relatively low in uncomplicated disease but increased substantially in patients with concomitant infective endocarditis. ROC analysis demonstrated AUC values of 0.91 for CRP, 0.88 for TNF-α, 0.84 for IL-10, and 0.71 for PCT. The combination of CRP and TNF-α yielded the highest diagnostic performance, with an AUC of 0.95, sensitivity of 93%, and specificity of 90%.

Conclusion. A multimarker approach combining systemic inflammatory and cytokine markers may improve assessment of disease activity in pediatric CRHD. CRP and TNF-α demonstrated the strongest diagnostic performance, whereas IL-10 appeared to reflect compensatory anti-inflammatory activation. PCT may have particular value in identifying concomitant bacterial complications. The proposed Integral Inflammatory Index may provide a convenient summary of inflammatory burden but requires independent validation.

 

References

1.Abbas AK, Lichtman AH, Pillai S. Cellular and Molecular Immunology. 10th ed. Elsevier; 2024.

2.Abdel-Massih RC, Mehta A, Abdelwahab S. Inflammatory cytokines in acute rheumatic carditis: a prospective controlled study. Pediatr Cardiol. 2023;31(7):1004–1010.

3.Altman DG. Practical Statistics for Medical Research. London: Chapman & Hall; 2024.

4.Assicot M, Gendrel D, Carsin H, et al. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet. 1993;341(8844):515–518.

5.Ayoub EM, Majeed HA. Acute rheumatic fever and post-streptococcal reactive arthritis. Clin Infect Dis. 2022;31(6):1484–1488.

6.Beaton A, Okello E, Engelman D, et al. Echocardiography screening for rheumatic heart disease. Circulation. 2019;139(25):e115–e135.

7.Becker KL, Nylen ES, White JC, Müller B, Snider RH Jr. Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis. J Clin Endocrinol Metab. 2024;89(4):1512–1525.

8.Black S, Kushner I, Samols D. C-reactive protein. J Biol Chem. 2024;279:48487–48490.

9.Gewitz MH, Baltimore RS, Tani LY, et al. Revision of the Jones criteria for the diagnosis of acute rheumatic fever in the era of Doppler echocardiography. Circulation. 2015;131(20):1806–1818.

10.Guilherme L, Kalil J, Cunningham MW. Molecular mimicry in the autoimmune pathogenesis of rheumatic heart disease. Autoimmunity. 2021;39(1):31–39.

11.Hua H, Kong Q, Zhang H, et al. TNF-α and IL-10 in pediatric patients with rheumatic heart disease: a meta-analysis. Pediatr Cardiol. 2021;42(4):876–885.

12.Kaur S, Haleem A, Kishore J. Prognostic value of serum TNF-α and IL-6 levels in children with rheumatic carditis. Indian Heart J. 2020;72(5):436–441.

13.Kumar S, Gupta A, Singhal S. Cytokine profile in children with rheumatic heart disease: correlation with disease activity. Indian J Pediatr. 2020;87(9):715–722.

14.Kumar V, Abbas AK, Aster JC. Robbins and Cotran Pathologic Basis of Disease. 10th ed. Elsevier; 2021.

15.Karthikeyan G, Guilherme L. Acute rheumatic fever. Lancet. 2021;392(10142):161–174.

16.Marijon E, Mirabel M, Celermajer DS, Jouven X. Rheumatic heart disease. Lancet. 2012;379(9819):953–964.

17.Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111(12):1805–1812.

18.Schuetz P, Albrich W, Mueller B. Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future. BMC Med. 2011;9:107.

19.Singh P, Mehta A, Aggarwal R. Procalcitonin as a marker for differentiating bacterial complications in rheumatic fever. Pediatr Rheumatol Online J. 2019;17(1):41.

20.World Heart Federation. World Heart Federation criteria for echocardiographic diagnosis of rheumatic heart disease—an evidence-based guideline. Nat Rev Cardiol. 2012;9(5):297–309.

21.Ministry of Health of the Republic of Uzbekistan. National Clinical Protocol for Diagnosis and Treatment of Rheumatic Diseases in Children. Tashkent; 2022.

22.Ministry of Health of the Republic of Uzbekistan. Standards for Laboratory Assessment of Inflammatory Markers in Children. Tashkent; 2021.

Published

2026-09-24